Immunovant Q1 net loss $120.6M; initiates two registrational trials for IMVT-1402

Immunovant, Inc.

2026-Q1 EPS reported -$0.71

Cash of $598.9M provides runway through Graves' disease readout expected in 2027.
Net loss $120.6M ($0.71/share) vs $87.2M ($0.60) in prior-year quarter.
Initiated a second potentially registrational trial of IMVT-1402 in Graves' disease in June 2025.
Initiated a potentially registrational trial of IMVT-1402 in Sjögren's disease in June 2025.
Expects GD remission data from batoclimab proof-of-concept study at ATA meeting in September 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.